LBRX · Lb Pharmaceuticals Inc · Executive Compensation
$39.23
-1.77 (-4.32%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$1.32B
Shares
32.26M
Volume · Oct 21
247.16K
Avg daily vol (3M)
390.85K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Heather Turner | Chief Executive Officer | $11,884,985 |
| Anna Eramo | Chief Medical Officer | $2,376,939 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Heather Turner | Chief Executive Officer | $4,792,690 |
| Anna Eramo | Chief Medical Officer | $891,050 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Susan G. Kozauer, M.D. | Chief Medical Officer | Appointed | 2026-09-15 |
| Joseph M. Miller | Chief Financial Officer | Appointed | 2026-09-03 |
| Anna Eramo, M.D. | advisor | Appointed | 2026-06-10 |
| Anna Eramo, M.D. | Chief Medical Officer | Resigned | 2026-06-10 |
| Robert A. Lenz | Class I director | Appointed | 2026-03-10 |
Leadership
- Heather Turner CEO, Board Member
- Joseph M. Miller CFO
- Gad Soffer COO
- Robert A. Lenz Board Member